Tongtong An

List of Publications by Citations

31 papers	394 citations	9 h-index	19 g-index
35 ext. papers	577 ext. citations	4.6 avg, IF	2.91 L-index

#	Paper	IF	Citations
31	Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer. *Oncotarget*, **2016**, 7, 20810-24	3.3	63
30	Multiregion Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Osteosarcoma and Matched Pulmonary Metastases. *Cancer Research*, **2019**, 79, 7-20	10.1	63
29	Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs). *Journal of Thoracic Oncology*, **2017**, 12, 1766-1778	8.9	35
28	The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. *Clinical Cancer Research*, **2020**, 26, 892-901	12.9	34
27	Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells. *Clinical Cancer Research*, **2019**, 25, 5049-5060	12.9	31
26	Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2017**, 12, 1376-1387	8.9	29
25	Mechanistic Exploration of Cancer Stem Cell Marker Voltage-Dependent Calcium Channel α2δ1 Subunit-mediated Chemotherapy Resistance in Small-Cell Lung Cancer. *Clinical Cancer Research*, **2018**, 24, 2148-2158	12.9	29
24	ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane-based chemotherapy. *Thoracic Cancer*, **2019**, 10, 2088-2095	3.2	14
23	Survival difference between Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis. *Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research*, **2017**, 29, 553-560	3.8	10
22	A nomogram model to predict death rate among non-small cell lung cancer (NSCLC) patients with surgery in surveillance, epidemiology, and end results (SEER) database. *BMC Cancer*, **2020**, 20, 666	4.8	8
21	Survival comparison of right and left side non-small cell lung cancer in stage I-IIIA patients: A Surveillance Epidemiology and End Results (SEER) analysis. *Thoracic Cancer*, **2019**, 10, 459-471	3.2	8
20	Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer. *Thoracic Cancer*, **2018**, 9, 1166-1173	3.2	7
19	Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients. *Annals of Translational Medicine*, **2021**, 9, 33	3.2	7
18	Optimal first-line treatment for advanced thymic carcinoma. *Thoracic Cancer*, **2019**, 10, 2081-2087	3.2	6
17	Nomogram model for predicting cause-specific mortality in patients with stage I small-cell lung cancer: a competing risk analysis. *BMC Cancer*, **2020**, 20, 793	4.8	6
16	Effects of Surgery on Survival of Early-Stage Patients With SCLC: Propensity Score Analysis and Nomogram Construction in SEER Database. *Frontiers in Oncology*, **2020**, 10, 626	5.3	5
15	Nomogram to predict cause-specific mortality in extensive-stage small cell lung cancer: A competing risk analysis. *Thoracic Cancer*, **2019**, 10, 1788-1797	3.2	5

LIST OF PUBLICATIONS

14	Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma-A Retrospective Analysis of a Multicenter Clinical Study. *Frontiers in Molecular Biosciences*, **2021**, 8, 639892	5.6	5
13	Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the Surveillance, Epidemiology, and End Results database. *Thoracic Cancer*, **2019**, 10, 1193-1202	3.2	4
12	Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma. *Thoracic Cancer*, **2018**, 9, 291-297	3.2	4
11	Identification of serum biomarkers to predict pemetrexed/platinum chemotherapy efficacy for advanced lung adenocarcinoma patients by data-independent acquisition (DIA) mass spectrometry analysis with parallel reaction monitoring (PRM) verification. *Translational Lung Cancer Research*, **2021**, 10, 981-994	4.4	4
10	Clinical Characteristics and Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Single-Center Experience. *Frontiers in Oncology*, **2020**, 10, 1137	5.3	3
9	Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma. *Thoracic Cancer*, **2020**, 11, 1149-1159	3.2	2
8	A novel third generation EGFR tyrosine kinase inhibitor Abivertinib for EGFR T790M mutant Non-Small Cell Lung Cancer: a multicenter phase1/2 study. *Clinical Cancer Research*, **2021**,	12.9	1
7	A phase I study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancer. *Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research*, **2016**, 28, 12-8	3.8	1
6	Characterization of Microbiota in Cancerous Lung and the Contralateral Non-Cancerous Lung Within Lung Cancer Patients. *Frontiers in Oncology*, **2020**, 10, 1584	5.3	1
5	Significant Upregulation of HERV-K (HML-2) Transcription Levels in Human Lung Cancer and Cancer Cells.. *Frontiers in Microbiology*, **2022**, 13, 850444	5.7	1
4	Toripalimab in an advanced non-small cell lung cancer patient with poor general condition after multiline treatment: a case report. *Journal of International Medical Research*, **2021**, 49, 3000605211042988	1.4	0
3	Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world setting. *Journal of Thoracic Disease*, **2021**, 13, 1813-1821	2.6	0
2	Evaluation of different treatment strategies between right-sided and left-sided pneumonectomy for stage I-IIIA non-small cell lung cancer patients. *Journal of Thoracic Disease*, **2021**, 13, 1799-1812	2.6	0
1	Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients. *Cancer Cell International*, **2020**, 20, 590	6.4	